Human iPSC Enhancer Kit
Catalog No. K2010
A media additive to make reprogramming and expansion of human iPSCs more efficient
Cited by 17 Publications
2 Customer Reviews
(B)Effect of MAPK pathway inhibition on FGF9 mediated induction of Fgf23 expression. (D) Western blot analysis of FRS2 and ERK1/2 phosphorylation in UMR 106 cells. Cells were treated for 3h (Western blot) or 24h (qPCR analysis) with FGF9 (50ng/ml), EGF (50ng/ml), PD173074 (250nM), PD0325901 (100nM) and RAF265 (500nM) as indicated. Heparin (10g/ml) was added to all treatments with FGF9. Activation of Fgf23 is shown relative to transcript levels in vehicle treated cells (relative expression of 1). Expression values were normalized to Gapdh mRNA copies and are given as average with SEM (n3). Data were compared by 1 way ANOVA; asterisk indicates p<0.05 with respect to vehicle treated cells.
|Cat.No.||Inhibitor Name||Concentration (1000x)||Targeted Pathway and Function||Information|
|S1036||PD0325901||5 mM||ERK/MEK pathway. To inhibit differentiation.||MEK, IC50=0.33 nM.|
|S2924||CHIR-99021 (CT99021) HCl||1 mM||GSK3 pathway. To enhance proliferation and viability.||GSK-3α, IC50=10 nM;
GSK-3β, IC50=6.7 nM.
|S1459||Thiazovivin||0.4 mM||Rho/ROCK pathway. To promote durability.||ROCK, IC50=0.5 μM.|
|S1067||SB 431542||2 mM||TGFβ/ALK5 pathway. To improve reprogramming.||ALK5, IC50=94 nM.|
Human induced pluripotent stem cells (human iPSCs, hiPSCs), a Nobel prize-worthy discovery, hold enormous potential. They offer great promise for research and clinical applications, such as the modeling of human disease, screening of drug efficacy and safety, and ultimately serve as a source of autologous or allogeneic cells for regenerative medicine. Although rapid advances and adoption of this technology have already been accomplished, human iPSC generation is still a very slow (~4 weeks) and inefficient (≤ 0.01%) process. The slow kinetics and low efficiency of current human iPSC reprogramming and culture methods have been obstacles to impede their utility in biomedical research and clinical applications.
As future applications of human iPSC technology, genetic alteration for disease correction, loci-specific modulation for reporter systems and clone selection for preferred differentiation potential will require higher throughput and more reliable methods for clone derivation and characterization. Consequently, there is still a tremendous need for a safer, easier and more efficient procedure for human iPSC generation, which would also facilitate identifying and characterizing fundamental mechanisms of reprogramming.
To address some of the challenges of deriving and expanding human iPSCs, Selleck Chemicals launches a novel tool, Human iPSC Enhancer Kit. It is a mixture composed of 4 small molecule inhibitors, including PD0325901, CHIR99021, Thiazovivin, and SB431542, inhibiting ERK/MEK, GSK3, Rho/ROCK, and TGFβ/ALK pathway, respectively. The combination of these 4 stem cells enhancers has been shown to effectively enhance reprogramming and survival of human iPSCs.
 Lin T, et al. A chemical platform for improved induction of human iPSCs. Nat Methods,2009, 6(11), 805-808.
 Valamehr B, et al. A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs. Sci Reports,2012, 2, 213.
|Formulation||Four specific signaling pathway inhibitors supplied as pre-dissolved DMSO solutions|
|Container||Screw Cap Micro Tubes of WATSON|
|Storage Instruction||Store at -20°C. Maintain under sterile conditions|